Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a note issued to investors on Saturday.

A number of other equities analysts also recently weighed in on TBPH. BTIG Research boosted their price target on Theravance Biopharma from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, June 27th. Jones Trading raised Theravance Biopharma to a “strong-buy” rating and set a $24.00 price target on the stock in a research report on Tuesday, June 17th.

Theravance Biopharma Stock Up 1.6%

Shares of NASDAQ TBPH opened at $13.15 on Friday. The business’s 50 day moving average price is $11.19 and its two-hundred day moving average price is $9.99. The company has a market cap of $657.51 million, a PE ratio of 54.79 and a beta of 0.01. Theravance Biopharma has a twelve month low of $7.88 and a twelve month high of $13.25.

Insider Activity

In other news, SVP Rhonda Farnum sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the sale, the senior vice president owned 326,918 shares in the company, valued at $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 44,000 shares of company stock worth $491,800 in the last three months. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP boosted its holdings in shares of Theravance Biopharma by 11.9% during the first quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company’s stock worth $1,628,000 after acquiring an additional 19,363 shares during the period. Rhumbline Advisers boosted its stake in shares of Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company’s stock valued at $556,000 after buying an additional 2,293 shares during the period. Geode Capital Management LLC boosted its stake in shares of Theravance Biopharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company’s stock valued at $8,121,000 after buying an additional 4,823 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Theravance Biopharma by 16.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company’s stock valued at $610,000 after buying an additional 9,315 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Theravance Biopharma by 1.5% in the first quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 1,720 shares during the period. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.